A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 342 participants.
Also called NCT06863987
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 342 participants
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Registry
-
NCT06863987
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06863987. Allocation not applicable; double masking; primary purpose treatment. Start 2025-02-05 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
- Condition
- Essential Hypertension
- Intervention (Drug)
- Valsartan Oral Solution
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTD
Record details
- Record id
cardio:ct-nct06863987- Content hash
deb0bd9c643188d6316d9513e55591c9c7f7a866a0a4035c2e6a25d46e5b5084